EN | RU
EN | RU

Help Support

Back

Tetracycline-levofloxacin is superior to amoxicillin-levofloxacin quadruple therapy for H. pylori

Tetracycline-levofloxacin is superior to amoxicillin-levofloxacin quadruple therapy for H. pylori Tetracycline-levofloxacin is superior to amoxicillin-levofloxacin quadruple therapy for H. pylori
Tetracycline-levofloxacin is superior to amoxicillin-levofloxacin quadruple therapy for H. pylori Tetracycline-levofloxacin is superior to amoxicillin-levofloxacin quadruple therapy for H. pylori

What's new?

Compared to amoxicillin-levofloxacin, the tetracycline-levofloxacin quadruple therapy can successfully eliminate H. pylori.

For second-line therapy of H. pylori infection, a ten-day tetracycline-levofloxacin (TL) quadruple therapy is more effective than amoxicillin-levofloxacin (AL) quadruple therapy. Investigators examined the efficacies of TL and AL quadruple therapy for H. pylori eradication.

Following the failure of first-line therapies, H. pylori-infected participants were randomized to receive either AL quadruple therapy (amoxicillin 500 mg four times a day [QID], levofloxacin 500 mg once a day [QD], esomeprazole 40 mg twice a day [BID], and tripotassium dicitrato bismuthate 300 mg QID) or TL quadruple therapy (500 mg tetracycline QID, 500 mg levofloxacin QD, 40 mg esomeprazole BID, and 300 mg tripotassium dicitrato bismuthate QID) for ten days. The post-therapy H. pylori status was checked six weeks following the end of therapy.

As per the intention-to-treat analysis, the TL quadruple group exhibited a better cure of  H. pylori infection than the AL quadruple group. Both TL and AL quadruple groups showed comparable frequencies of adverse events and drug adherence (Table 1).


Additional assessment illustrated that the TL quadruple treatment had a high elimination rate for both levofloxacin-resistant and susceptible strains (88.9% and 100%). Conversely, the AL quadruple treatment offers a high elimination for levofloxacin-susceptible strains (90.9%) but a poor elimination efficacy for the levofloxacin-resistant strains (50%).

Thus, TL quadruple therapy exhibits better efficacy than AL quadruple therapy for H. pylori elimination in a population having high levofloxacin resistance.

Source:

Helicobacter

Article:

Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection

Authors:

Ping-I Hsu et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: